JP2012527447A5 - - Google Patents

Download PDF

Info

Publication number
JP2012527447A5
JP2012527447A5 JP2012511409A JP2012511409A JP2012527447A5 JP 2012527447 A5 JP2012527447 A5 JP 2012527447A5 JP 2012511409 A JP2012511409 A JP 2012511409A JP 2012511409 A JP2012511409 A JP 2012511409A JP 2012527447 A5 JP2012527447 A5 JP 2012527447A5
Authority
JP
Japan
Prior art keywords
composition
pharmaceutically acceptable
liquid composition
levodopa
kit
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012511409A
Other languages
English (en)
Other versions
JP2012527447A (ja
JP5643297B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IL2010/000400 external-priority patent/WO2010134074A1/en
Publication of JP2012527447A publication Critical patent/JP2012527447A/ja
Publication of JP2012527447A5 publication Critical patent/JP2012527447A5/ja
Application granted granted Critical
Publication of JP5643297B2 publication Critical patent/JP5643297B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Claims (14)

  1. アルギニン、レボドパ及びカルビドパ含む薬学的に許容可能な液体組成物であって、該組成物は、1:1.5〜1:2.5から選択されるレボドパ:アルギニンモル比、及び約8.5から約10のpHを有し;及び、該組成物は、48時間以上の間、25℃で実質的に安定である、上記液体組成物。
  2. 1重量%より多くの、又は2重量%、3重量%、4重量%、5重量%、6重量%若しくはより多くのレボドパを含む、請求項に記載の薬学的に許容可能な液体組成物。
  3. N−メチルピロリドン、ポリビニルピロリドン、プロピレングリコール、酸化防止剤、又はそれらの組み合わせから選択される薬学的に許容可能な賦形剤を更に含む、請求項1又は2に記載の薬学的に許容可能な液体組成物。
  4. 水を更に含む、請求項1からまでのいずれか一項に記載の薬学的に許容可能な液体組成物。
  5. エンタカポン又はトルカポンを更に含む、請求項1からまでのいずれか一項に記載の薬学的に許容可能な液体組成物。
  6. 前記液体組成物が、25℃で約8.5から約9.5のpHを有する、請求項1から5までのいずれか一項に記載の薬学的に許容可能な液体組成物。
  7. a)請求項1からまでのいずれか一項に記載の液体組成物を含む、連続投与に適した第1の組成物
    b)レボドパ又はその薬学的に許容可能な塩若しくはエステルを含む、経口投与に適した第2の組成物、及び任意選択で
    c)第2の組成物と併用する第1の組成物の投与に関する指示書
    を含むキット。
  8. 連続投与用の前記第1の組成物は、経皮、皮内、皮下、静脈内、又は十二指腸内投与用である、請求項に記載のキット。
  9. 前記連続投与が注入ポンプの使用を含む、請求項に記載のキット。
  10. 第2の組成物は、カルビドパ、ベンセラジド、エンタカポン、トルカポン、又はそれらの組み合わせを更に含む、請求項からのいずれか一項に記載のキット。
  11. 第2の組成物はレボドパの薬学的に許容可能な塩を含む、請求項から10までのいずれか一項に記載のキット。
  12. 第2の組成物はレボドパのアルギニン塩を含む、請求項11に記載のキット。
  13. 不穏下肢症候群、パーキンソン病、続発性パーキンソン症候群、ハンチントン病、パーキンソン様症候群、進行性核上性麻痺、多系統萎縮症、又は筋萎縮性側索硬化症から選択される神経学的障害の治療における使用のための、請求項から12のいずれか一項に記載のキット。
  14. パーキンソン病の治療における使用のための、請求項13に記載のキット。
JP2012511409A 2009-05-19 2010-05-17 ドーパデカルボキシラーゼ阻害剤の連続投与のための組成物 Active JP5643297B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17951109P 2009-05-19 2009-05-19
US61/179,511 2009-05-19
PCT/IL2010/000400 WO2010134074A1 (en) 2009-05-19 2010-05-17 Compositions for continuous administration of dopa decarboxylase inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014221786A Division JP5921002B2 (ja) 2009-05-19 2014-10-30 ドーパデカルボキシラーゼ阻害剤の連続投与のための組成物

Publications (3)

Publication Number Publication Date
JP2012527447A JP2012527447A (ja) 2012-11-08
JP2012527447A5 true JP2012527447A5 (ja) 2014-05-29
JP5643297B2 JP5643297B2 (ja) 2014-12-17

Family

ID=42320738

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2012511409A Active JP5643297B2 (ja) 2009-05-19 2010-05-17 ドーパデカルボキシラーゼ阻害剤の連続投与のための組成物
JP2014221786A Active JP5921002B2 (ja) 2009-05-19 2014-10-30 ドーパデカルボキシラーゼ阻害剤の連続投与のための組成物
JP2016078121A Active JP6157678B2 (ja) 2009-05-19 2016-04-08 ドーパデカルボキシラーゼ阻害剤の連続投与のための組成物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2014221786A Active JP5921002B2 (ja) 2009-05-19 2014-10-30 ドーパデカルボキシラーゼ阻害剤の連続投与のための組成物
JP2016078121A Active JP6157678B2 (ja) 2009-05-19 2016-04-08 ドーパデカルボキシラーゼ阻害剤の連続投与のための組成物

Country Status (26)

Country Link
US (9) US8193243B2 (ja)
EP (3) EP3192500B1 (ja)
JP (3) JP5643297B2 (ja)
KR (2) KR101709904B1 (ja)
CN (2) CN102438587B (ja)
AR (3) AR078413A1 (ja)
AU (1) AU2010250766B2 (ja)
BR (1) BRPI1011031B8 (ja)
CA (1) CA2761624C (ja)
CL (1) CL2011002895A1 (ja)
CY (1) CY1119495T1 (ja)
DK (2) DK3192500T3 (ja)
ES (2) ES2840748T3 (ja)
HR (2) HRP20170805T1 (ja)
HU (2) HUE033388T2 (ja)
IL (1) IL216383A (ja)
LT (1) LT2432454T (ja)
MX (2) MX364974B (ja)
NZ (1) NZ596963A (ja)
PL (2) PL3192500T3 (ja)
PT (2) PT2432454T (ja)
RU (3) RU2559083C9 (ja)
SG (3) SG176159A1 (ja)
SI (1) SI2432454T1 (ja)
WO (1) WO2010134074A1 (ja)
ZA (1) ZA201109037B (ja)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN192600B (ja) * 1996-10-18 2004-05-08 Hoechst Celanese Corp
JP5643297B2 (ja) 2009-05-19 2014-12-17 ニューロデルム リミテッド ドーパデカルボキシラーゼ阻害剤の連続投与のための組成物
ES2660772T3 (es) * 2010-11-15 2018-03-26 Neuroderm Ltd Administración continua de L-dopa, inhibidores de dopa descarboxilasa, inhibidores de catecol-o-metil transferasa y composiciones para ello
CN107693486A (zh) 2012-06-05 2018-02-16 纽罗德姆有限公司 包含阿朴吗啡和有机酸的组合物及其用途
ITBO20120368A1 (it) 2012-07-06 2014-01-07 Alfa Wassermann Spa Composizioni comprendenti rifaximina e amminoacidi, cristalli di rifaximina derivanti da tali composizioni e loro uso.
CN103845318A (zh) * 2012-12-07 2014-06-11 天津市汉康医药生物技术有限公司 恩他卡朋分散片
JP6472391B2 (ja) 2013-03-13 2019-02-20 ニューロダーム リミテッドNeuroderm Ltd パーキンソン病の治療方法
WO2015069773A1 (en) * 2013-11-05 2015-05-14 Synagile Corporation Devices and methods for continuous drug delivery via the mouth
EP3777833B1 (en) * 2014-03-13 2023-10-18 Neuroderm Ltd. Dopa decarboxylase inhibitor compositions
US10258585B2 (en) 2014-03-13 2019-04-16 Neuroderm, Ltd. DOPA decarboxylase inhibitor compositions
EP3188725B1 (en) * 2014-09-04 2020-10-28 Lobsor Pharmaceuticals Aktiebolag Pharmaceutical compositions comprising levodopa, a dopamine decarboxylase inhibitor and a comt inhibitor and method of administration thereof
RU2743347C2 (ru) 2014-10-21 2021-02-17 Эббви Инк. Пролекарства карбидопа и l-dopa и их применение для лечения болезни паркинсона
MA41377A (fr) 2015-01-20 2017-11-28 Abbvie Inc Gel intestinal de lévodopa et de carbidona et procédés d'utilisation
JP6982870B2 (ja) * 2015-05-06 2021-12-17 シンアジャル コーポレイション 薬物粒子を含有する医薬懸濁液、それらの投与のためのデバイス、およびそれらの使用方法
US10555922B2 (en) 2015-09-04 2020-02-11 Lobsor Pharmaceuticals Aktiebolag Method of treating a dopamine related disorder in a subject by administering levodopa, in combination with a dopamine decarboxylase inhibitor and a catechol-o-methyltransferase inhibitor
BR112018010564A2 (pt) 2015-11-24 2018-11-21 Neuroderm Ltd. composições farmacêuticas compreendendo levodopa amida e usos das mesmas
JP7095873B2 (ja) * 2016-04-11 2022-07-05 ユニバーシティ・オブ・キャンベラ レボドパ、抗酸化剤及び水性担体を含む眼科用組成物
US10064834B2 (en) 2016-05-09 2018-09-04 Texas Tech University System Carbidopa for the treatment of cancer
KR102437003B1 (ko) 2017-06-05 2022-08-26 디즐린 파마슈티컬스 아베 레보도파 주입 용액
US20230123806A1 (en) * 2017-07-07 2023-04-20 Neuroderm, Ltd. Device for subcutaneous delivery of fluid medicament
CA3095341A1 (en) * 2018-03-29 2019-10-03 Avion Pharmaceuticals, Llc Levodopa fractionated dose composition and use
WO2020252257A1 (en) * 2019-06-12 2020-12-17 President And Fellows Of Harvard College Methods and compositions for modulation of an interspecies gut bacterial pathway for levodopa metabolism
US11213502B1 (en) 2020-11-17 2022-01-04 Neuroderm, Ltd. Method for treatment of parkinson's disease
US11331293B1 (en) 2020-11-17 2022-05-17 Neuroderm, Ltd. Method for treatment of Parkinson's disease
US11844754B2 (en) 2020-11-17 2023-12-19 Neuroderm, Ltd. Methods for treatment of Parkinson's disease
WO2023126945A1 (en) * 2022-01-03 2023-07-06 Neuroderm, Ltd. Methods and compositions for treating parkinson's disease

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3769424A (en) * 1970-10-01 1973-10-30 Merck & Co Inc Composition and method of treating dopamine deficiency in brain tissue
AU6889274A (en) * 1973-05-17 1975-11-20 Astra Laekemedel Ab Treatment of neurological disorders
US3936495A (en) * 1973-11-27 1976-02-03 Merck & Co., Inc. Purification process
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4241082A (en) * 1977-09-02 1980-12-23 Sankyo Company Limited Agents for promoting reproductive ability of domestic animals
JPS5450700A (en) 1977-09-28 1979-04-20 Sankyo Co Glazing agent of animal leather
JPS6021570B2 (ja) * 1978-07-04 1985-05-28 三共株式会社 ド−パ類の高濃度製剤の製法
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
US4642316A (en) * 1985-05-20 1987-02-10 Warner-Lambert Company Parenteral phenytoin preparations
DE3779500T2 (de) * 1986-06-10 1993-01-21 Chiesi Farma Spa Levodopa-methyl-ester enthaltende pharmazeutische zusammensetzungen, ihre herstellung und therapeutische verwendungen.
US4684666A (en) * 1986-08-19 1987-08-04 Haas Pharmaceuticals, Inc. Stabilized liquid analgesic compositions
US4963568A (en) 1989-05-31 1990-10-16 Abbott Laboratories Dopamine agonists
US5350769A (en) * 1990-10-30 1994-09-27 Ss Pharmaceutical Co., Ltd. Antiinflammatory gel preparation
US5877176A (en) 1991-12-26 1999-03-02 Cornell Research Foundation, Inc. Blocking induction of tetrahydrobiopterin to block induction of nitric oxide synthesis
CA2143070C (en) * 1994-02-22 2001-12-18 Pankaj Modi Oral controlled release liquid suspension pharmaceutical formulation
GB9523833D0 (en) 1995-11-22 1996-01-24 Boots Co Plc Medical treatment
US5861423A (en) * 1997-02-21 1999-01-19 Caldwell; William Scott Pharmaceutical compositions incorporating aryl substituted olefinic amine compounds
AU1917899A (en) * 1998-03-20 1999-10-18 Warner-Lambert Company Crystalline sodium phenytoin monohydrate
US7201923B1 (en) * 1998-03-23 2007-04-10 General Mills, Inc. Encapsulation of sensitive liquid components into a matrix to obtain discrete shelf-stable particles
HU228771B1 (en) * 1998-05-15 2013-05-28 Warner Lambert Co Stabilized pharmaceutical preparations of gamma-aminobutyric acid derivatives and process for preparing the same
US6274168B1 (en) * 1999-02-23 2001-08-14 Mylan Pharmaceuticals Inc. Phenytoin sodium pharmaceutical compositions
US6716452B1 (en) * 2000-08-22 2004-04-06 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
WO2000054773A1 (en) 1999-03-12 2000-09-21 Nitromed, Inc. Dopamine agonists in combination with nitric oxide donors, compositions and methods of use
FI109453B (fi) 1999-06-30 2002-08-15 Orion Yhtymae Oyj Farmaseuttinen koostumus
US7479498B2 (en) * 1999-08-23 2009-01-20 Phoenix Biosciences, Inc. Treatments for viral infections
US6348965B1 (en) * 1999-09-24 2002-02-19 Henry Palladino Solid state fluorescence and absorption spectroscopy
SE0001151D0 (sv) 2000-03-31 2000-03-31 Amarin Dev Ab Method for producing a controlled-release composition
US20020028799A1 (en) 2000-07-06 2002-03-07 Naylor Alasdair Mark Treatment of male sexual dysfunction
GB0017387D0 (en) * 2000-07-14 2000-08-30 Pfizer Ltd Novel enzyme
US20020099013A1 (en) 2000-11-14 2002-07-25 Thomas Piccariello Active agent delivery systems and methods for protecting and administering active agents
US20030119714A1 (en) 2000-12-15 2003-06-26 Naylor Alasdair Mark Treatment of male sexual dysfunction
WO2003050261A2 (en) 2001-12-10 2003-06-19 Bristol-Myers Squibb Company (1-phenyl-2-heteroaryl)ethyl-guanidine compounds as inhibitors of mitochondrial f1f0 atp hydrolase
BR0309113A (pt) * 2002-04-11 2005-02-01 Ranbaxy Lab Ltd Composições farmacêuticas de liberação controlada de carbidopa e levodopa e processo para a preparação das mesmas
US7985422B2 (en) 2002-08-05 2011-07-26 Torrent Pharmaceuticals Limited Dosage form
CA2500320A1 (en) 2002-10-10 2004-04-29 Morphochem Aktiengesellschaft Fuer Kombinatorische Chemie Novel compounds with antibacterial activity
CN1826170B (zh) * 2003-07-18 2010-12-08 巴克斯特国际公司 通过受控相分离制备的小球形颗粒的制造方法、其用途和成分
US7589233B2 (en) * 2003-07-29 2009-09-15 Signature R&D Holdings, Llc L-Threonine derivatives of high therapeutic index
US8173840B2 (en) 2003-07-29 2012-05-08 Signature R&D Holdings, Llc Compounds with high therapeutic index
GB0319935D0 (en) 2003-08-26 2003-09-24 Cipla Ltd Polymorphs
WO2005023185A2 (en) * 2003-08-29 2005-03-17 Transform Pharmaceuticals, Inc. Pharmaceutical compositions and method of using levodopa and carbidopa
US20050053669A1 (en) 2003-09-05 2005-03-10 Boehringer Ingelheim International Gmbh Administration form for the oral application of poorly soluble acidic and amphorteric drugs
JP2007509974A (ja) * 2003-10-31 2007-04-19 アルザ・コーポレーシヨン 3−アミノプロピル−n−ブチルホスフィン酸の増大した吸収のための組成物および薬用量形態
CN1901881A (zh) * 2003-10-31 2007-01-24 阿尔扎公司 用于增强的吸收的组合物和剂型
WO2005099678A1 (en) 2004-04-06 2005-10-27 Transform Pharmaceuticals, Inc. Pharmaceutical compositions and method of using levodopa and carbidopa
SE0401842D0 (sv) * 2004-07-12 2004-07-12 Dizlin Medical Design Ab Infusion and injection solution of levodopa
SI1797109T1 (sl) * 2004-09-09 2016-07-29 Yeda Research And Development Co., Ltd. Zmesi polipeptidov, sestavki, ki jih vsebujejo, in postopki za njihovo pripravo ter njihove uporabe
WO2006037061A2 (en) * 2004-09-28 2006-04-06 Farouk Karoum Compositions and methods of using d-dopa to treat parkinson's disease
WO2006043532A1 (ja) * 2004-10-19 2006-04-27 Ono Pharmaceutical Co., Ltd. パーキンソン病治療剤
DE102006021872B4 (de) 2006-05-11 2008-04-17 Sanofi-Aventis 4,5-Diphenyl-pyrimidinyl-oxy oder -mercapto substituierte Carbonsäuren, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
AU2007267135B2 (en) 2006-05-31 2013-03-07 AbbVie Pharmaceuticals GmbH Long term 24 hour intestinal administration of levodopa/carbidopa
US8058243B2 (en) 2006-10-13 2011-11-15 Hsc Research And Development Limited Partnership Method for treating a brain cancer with ifenprodil
US8563013B2 (en) * 2007-04-06 2013-10-22 Janssen Biotech, Inc. Systems and methods for delivering a fluid drug
CN101669925B (zh) 2008-09-10 2011-08-10 天津药物研究院 干粉吸入剂、其制备方法和用途
US20130253056A1 (en) 2009-05-19 2013-09-26 Neuroderm, Ltd. Continuous Administration of Levodopa and/or Dopa Decarboxylase Inhibitors and Compositions for Same
JP5643297B2 (ja) 2009-05-19 2014-12-17 ニューロデルム リミテッド ドーパデカルボキシラーゼ阻害剤の連続投与のための組成物
CN101987081B (zh) 2010-07-16 2012-08-08 钟术光 一种控释制剂
KR101187064B1 (ko) 2010-07-18 2012-09-28 주식회사 바이오폴리메드 양이온성 지질, 이의 제조 방법 및 이를 포함하는 세포내 이행성을 갖는 전달체
US10150792B2 (en) 2010-11-08 2018-12-11 Synthonics, Inc. Bismuth-containing compounds, coordination polymers, methods for modulating pharmacokinetic properties of biologically active agents, and methods for treating patients
DK2640370T3 (en) 2010-11-15 2018-06-25 Neuroderm Ltd COMPOSITIONS FOR TRANSDERMAL DELIVERY OF ACTIVE RESOURCES
ES2660772T3 (es) 2010-11-15 2018-03-26 Neuroderm Ltd Administración continua de L-dopa, inhibidores de dopa descarboxilasa, inhibidores de catecol-o-metil transferasa y composiciones para ello
BR112013014304A2 (pt) 2010-12-10 2016-07-19 Synagile Corp composições de pró-fármaco levodopa infundíveis subcutaneamente e método de infusão
WO2013061161A2 (en) 2011-10-28 2013-05-02 Green Bcn Consulting Services Sl New combination therapies for treating neurological disorders
JP6472391B2 (ja) 2013-03-13 2019-02-20 ニューロダーム リミテッドNeuroderm Ltd パーキンソン病の治療方法
EP3777833B1 (en) 2014-03-13 2023-10-18 Neuroderm Ltd. Dopa decarboxylase inhibitor compositions

Similar Documents

Publication Publication Date Title
JP2012527447A5 (ja)
HRP20170805T1 (hr) Pripravak za kontinuiranu primjenu inhibiotra dopa dekarboksilaze
NZ610911A (en) Continuous administration of l-dopa, dopa decarboxylase inhibitors, catechol-o-methyl transferase inhibitors and compositions for same
JP2016512230A5 (ja)
HRP20171512T1 (hr) Derivati betulina
UA113165C2 (xx) Застосування комбінації баклофену і акампросату для лікування неврологічних захворювань та композиція, яка містить баклофен і акампросат
MX2022007264A (es) Mejoramiento de autofagia o incremento de longevidad por administracion de urolitinas o precursores de las mismas.
MX355742B (es) Análogos deuterados del ácido 4-hidroxibutírico.
WO2012116290A3 (en) Neuroactive 17(20)-z-vinylcyano-substituted steroids, prodrugs thereof, and methods of treatment using same
CA2918938C (en) Substituted aminopyrimidine compounds and methods of use
WO2011113013A3 (en) Methods and compositions for treating viral or virally-induced conditions
MY156188A (en) Long - acting formulations of insulins
WO2012087976A3 (en) Novel inhibitors of hepatitis c virus replication
MX352647B (es) Metodo para temporizar una colonoscopia en donde se administra una composicion de picosulfato.
EA201490748A1 (ru) Лечение рассеянного склероза комбинацией лахинимода и финголимода
MY174002A (en) Combination theraphy for the treatment of diabetes
HK1167641A1 (en) 4-hydroxybutyric acid analogs 4-
JP2013542247A5 (ja)
JP2015502974A5 (ja)
HRP20211442T1 (hr) Kombinacija za liječenje parkinsonove bolesti
BR112012018116A2 (pt) "hormônios do crescimento com eficácia in vivo prolongada"
GEP20166488B (en) Co-crystals and salts of ccr3-inhibitors
WO2013028818A8 (en) Pyrimido- pyridazinone compounds and use thereof
WO2014085453A3 (en) Small molecule lxr inverse agonists
WO2008008882A3 (en) Glucocorticoid receptor modulator and methods of use